mesenchymal stem cells, cardiac progenitor cells, human embryonic stem cells (hESCs), and human induced pluripotent stem cells (iPSCs) have been investigated in both clinical and preclinical studies. [5] [6] [7] [8] [9] [10] [11] Although adult stem cells have demonstrated some clinical benefit, the potential of hESC-and iPSC-derived cardiac myocytes is not fully explored. hESCs and iPSCs differentiate robustly into a highly purified population of functional cardiac myocytes in vitro. 12, 13 Functional improvement of the injured myocardium has been observed in murine, rodent, and porcine models that received either hESCs-derived cardiac myocytes (hCMs) 12, [14] [15] [16] [17] [18] [19] [20] or iPSCsderived cardiac myocytes (iCMs). 21, 22 Additionally, pluripotent stem cell-derived cardiac myocytes have been shown to engraft and improve heart function more effectively than noncardiac derivatives. 12, [17] [18] [19] However, the engraftment is not permanent, and the mechanism of action underlying the advantages of cardiac lineage differentiation is not clearly understood. It seems that the injured cardiac myocytes are salvaged via paracrine release of cytokines and growth factors from the transplanted hCMs and iCMs, which result in functional improvement. Paracrine factors constitute the key contributors with pleiotropic effects, including anti-inflammation, antiapoptosis, antifibrosis, and proangiogenesis. Thus, transplanted stem cells may accelerate the restoration of the injured cardiac tissue through physiological and sustained release of key cytokines. [22] [23] [24] [25] The aim of this investigation is to evaluate whether cardiac differentiation of pluripotent stem cells may repair the ischemic myocardium. Systematic investigation of undifferentiated pluripotent stem cells (hESCs and iPSCs) and their cardiac-differentiated derivatives (hCMs and iCMs) is performed, using novel multimodality evaluations of cell engraftment, myocardial viability, and cardiac function. These in vivo findings are then validated by ex vivo cellular and molecular assays to confirm paracrine mechanism of action.
Methods
Detailed experimental methods are available in the Online Data Supplement.
Cell Preparations
hESCs line H7 were purchased from WiCell Research Institute. 26 Monoclonal iPSCs lines were generated by infection of blood mononuclear cells with nonintegrating Sendai virus delivering octamerbinding transcription factor 3/4 (OCT3/4), sex determining region-Y (SRY)-box 2 (SOX2), Krueppel-like factor 4 (KLF4), L-MYC, LIN-28, short-hairpin RNA for P53, and Epstein-Barr nuclear antigen 1 (EBNA1). 27, 28 Zinc finger nuclease technology was used to integrate a reporter gene containing firefly luciferase. 29 
Electrophysiology of hCMs and iCMs
Whole-cell action potentials were recorded by standard patch-clamp technique, as described previously. 13, 30, 31 
Acute Myocardial Injury Model and Intramyocardial Delivery of Cells
All experimental protocols were approved by the administrative panel on Laboratory Animal Care at Stanford School of Medicine. Myocardial injuries (MIs) were induced in severe combined immunodeficient beige male mice (90-120 days; Charles River Laboratories) by ligation of the mid left anterior descending coronary artery through a left thoracotomy. A blinded surgeon injected 60 µL of following cells (500 000) in a 50:50 mixture of PBS and Matrigel (Corning) into the anterolateral wall: (1) hESCs (n=9), (2) iPSCs (n=8), (3) hCMs (n=9), (4) iCMs (n=14), and (5) PBS control (n=10). 
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Novelty and Significance
What Is Known?
• hCMs and iCMs mitigate damage of the injured myocardium.
• Cardiac function improves despite suboptimal engraftment and eventual death of the transplanted stem cells.
What New Information Does This Article Contribute?
• iCMs and hCMs secrete cytokines that target the restorative genes and pathways of the injured myocardium.
• Cell therapy does not stimulate cardiac myocyte proliferation or regeneration but hypertrophy and salvage of the injured cardiac myocytes in the PIR.
Preclinical studies have reported functional benefit by iCMs and hCMs, despite their suboptimal engraftment in the myocardium.
Little is known about the underlying mechanism. We investigated the efficacy of undifferentiated pluripotent stem cells versus their cardiac lineage derivatives in a murine MI model. Cardiac function significantly improved in the iCM-and hCM-treatment groups. Our data confirm the production of reparative cytokines that modulate antiapoptotic, proangiogenic, and promigratory activity, resulting in cardiac myocyte hypertrophy and improved contractility in the PIR. This study demonstrates that cardiac differentiation of pluripotent stem cells improves the therapeutic efficacy through paracrine mechanism to mitigate damage of the injured myocardium.
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Magnetic Resonance Imaging
Mice were imaged at weeks 2 and 4 after left anterior descending coronary artery ligation to evaluate LVEF and myocardial viability. Mice were injected with 0.7 cc/kg of SeeMore (Eagle Vision Pharmaceutical) intraperitoneally before manganese-enhanced magnetic resonance imaging (MRI) acquisition. 32, 33 MRI scanning was randomized, and the reader for the study interpretation was blinded.
Bioluminescence Imaging
Optical Bioluminescence imaging (BLI) was performed at weeks 2 and 4 after left anterior descending coronary artery ligation.
Ex Vivo Immunohistochemistry of the Myocardium
Immunohistochemistry (IHC) assays of mouse myocardium were performed at week 4 after left anterior descending coronary artery ligation. Sectioning and hematoxylin and eosin (H&E) staining were performed by a blinded pathologist. For other immunochemical analyses, the specimen demonstrated experimental conditions and required specific techniques to assess the reagents. These conditions may have unblinded the researcher.
Evaluation of the In Vitro Release of the Cytokines From Cultured Cells
hESCs, iPSCs, hCMs, and iCMs (500 000 cells) were cultured in normoxic conditions for 24 hours. Their supernatants were harvested and analyzed by Luminex Multiplex Assay (Thermo Fisher Scientific).
Ex Vivo Real-Time Reverse Transcription Polymerase Chain Reaction Analysis of the Myocardium Tissues
Total RNA was isolated from cell-treated, control, and wild-type myocardium at the end of the study, reverse transcribed into cDNA, and analyzed for gene expression by real-time reverse transcription polymerase chain reaction (RT-PCR).
Results
Electrophysiological Characterization of the In Vitro hCMs and iCMs
To validate the cardiac phenotype and compare the contractility of hESC-and iPSC-derived cardiac myocytes, we performed action potential patch-clamp analyses. At days 22 to 28 of differentiation, sample populations of hCMs and iCMs displayed action potentials of 3 major cardiac subtypes, ventricular, atrial, and nodal-like cardiac myocytes. By comparisons of multiple key action potentials, we determined that hCMs and iCMs were electrophysiologically and functionally similar (Online Table I ; Online Figure I ).
Sustained Engraftment of hCMs and iCMs Correlated With Improved LVEF
To test whether cardiac differentiation improves cardiac function, we measured LVEF by cardiac MRI ( Figure 1A and 1B). At week 4, mice treated with cardiac myocytes exhibited significantly improved LVEF compared with the control group (hCMs 36.1%, P<0.05 and iCMs 36.6%, P<0.05 versus control 19.8%; week 4). The hCM and iCM groups also showed a significantly improved LVEF compared with their undifferentiated pluripotent stem cells (hESC and iPSC groups) at week 4. Notably, the hCM and iCM groups demonstrated significantly improved LVEF between weeks 2 and 4. In contrast, mice treated with hESCs, iPSCs, or the control had decreased LVEF between weeks 2 and 4 ( Figure 1A and 1B). These findings suggest that treatment with differentiated cardiac myocytes not only improve LVEF significantly compared with pluripotent stem cells or control but prevent the progressive deterioration of LV function.
Although LVEF remains the gold standard in evaluating cardiac function, we sought to further characterize the extent of injury and repair in the peri-infarct region (PIR). We directly quantified the volume of the viable myocardium by manganese-enhanced MRI at weeks 2 and 4 ( Figure 1D through 1G) . Manganese-enhanced MRI demonstrated significantly greater myocardial viability in the hCM and iCM groups compared with the control (hCMs, 73.4%; P<0.05 and iCMs, 65.6%; P<0.05 versus control 46.0%; week 4). Consistent with the LVEF results, mice treated with cardiac lineage cells (hCMs or iCMs) showed significantly improved myocardial viability compared with the hESC and iPSC groups, respectively. Furthermore, MRI measurements, including LV end-diastolic volume, myocardial viability volume, and infarct volume, were also performed (Online Table II ; Online Figure II ), demonstrating reduced infarct volume in hCM-and iCM-treated animals. Finally, a significant correlation was found between LVEF and myocardial viability (R=0.76 and P<0.001; Figure 1F ).
To determine whether these functional improvements correlated with sustained engraftment, we performed BLI to track the luciferase-tagged stem cells or cardiac myocytes ( /sr; P<0.05; week 2). However, these BLI signals were reduced by week 4, indicating decreasing engraftment. Although hCMs and iCMs appeared to engraft in the myocardium between weeks 2 and 4, little-to-no signal was found in the hESC or iPSC groups by week 2 and was virtually absent by week 4. These findings suggest that cardiac differentiation reduces death of implanted cells in the myocardium. BLI measurements of all groups can be found in Online Table II . To derive a relationship between BLI signal and absolute cell number, in vitro BLI analyses were performed using iCMs as a representative cell line. Results demonstrate a significant linear correlation between cell number and BLI signal (R=0.99 and P<0.0001; Online Figure III ). BLI was, thus, validated as a tool to monitor viable cell number. Using this linear correlation, we estimated absolute transplanted cell numbers in each treatment group ( Figure 2D and 2E).
The mortality of the mice in each treatment group was the following: hESCs, 22%; iPSCs, 25%; hCMs, 11%; iCMs, 43%; and control, 20%. There were no significant differences between the groups.
Histological Evidence of hCM and iCM Engraftment
To validate our BLI results, myocardial sections were stained for human cardiac troponin T (cTnT) and human nuclear antibody ( Figure 3 ). Despite this limited engraftment, viable myocardium in the PIR greatly increased , demonstrating a volume of >1000-fold greater than the xenograft. This significant discrepancy suggests that the microscopic population of engrafted cardiac cells could not account for the entire volume of increased viable myocardium by replacing scar tissue; instead, surviving hCMs and iCMs may have salvaged the hibernating and injured myocardium by the widespread effects of their cytokines. No teratomas were detected in all groups (Online Figure IV) .
Cytokine Production of the Transplanted hCMs and iCMs
We studied the paracrine mechanism of action of the hCMs and iCMs to explain the significant discrepancy between the volume of increased myocardial viability and engrafted cardiac stem cells. To assess the paracrine effects of the transplanted cells, we analyzed the supernatant of each cell type by 63-plex Luminex immunoassay of human cytokines. There were significant differences in the cytokines of cardiac derivatives Figure 2 . Stem cell engraftment measured by bioluminescence imaging (BLI). A, BLI signals of human embryonic stem cells (hESCs), hESC-derived cardiac myocytes (hCMs), and control at weeks 2 and 4. The hCM group demonstrated sustained engraftment throughout the 4-week period, whereas the hESC group showed low levels of engraftment or cell death by week 2. B, Similarly, the induced pluripotent stem cells (iPSC)-derived cardiac myocyte (iCM) group indicated greater cell engraftment at weeks 2 and 4 vs control. The iPSC group had measurable engraftment signals at week 2 but showed no evidence of sustained engraftment at week 4. C, Robust engraftment in hCMs and iCMs at week 2 decreased by week 4. D, Absolute cell numbers were estimated in hESCs and hCMs, and (E) in iPSCs and iCMs. Data are presented as mean±SEM. *P<0.05. Figure 1 Continued. of hESCs, hCMs, and control at weeks 2 and 4 after cell transplantation. Myocardial viability is significantly greater in hCMs at week 4 vs control and hESCs at week 4 or hCMs at week 2. E, Myocardial viability of iPSCs, iCMs, and control at weeks 2 and 4 after cell transplantation. Myocardial viability is significantly greater in hCMs at week 4 vs control and hESCs at week 4 or hCMs at week 2. Conversely, the control group had significantly reduced myocardial viability between weeks 2 and 4. F, There is a significant positive correlation between LVEF and myocardial viability (R=0.76 and P<0.001). G, Myocardial viability in the peri-infarct region (PIR) as visualized by manganese-enhanced magnetic resonance imaging (MEMRI), highlighted with red arrows. Data are presented as mean±SEM. *P<0.05.
and pluripotent stem cells (Online Figure V) 
Cardiac Myocyte Transplantation Reduces Apoptosis in the PIR of the Recipient Myocardium
To evaluate the effect of cytokines on the host myocardium, we examined gene expression in the PIR at week 4.
RT-PCR in the hCM group demonstrated an upward trend of antiapoptosis (TNF-α ‡) compared with the hESC and control groups ( ‡P<0.3; Figure 4A and 4B). Similarly, the iCM group showed upregulation of antiapoptotic genes compared with control group (Akt1 and TNF-α; P<0.05; Figure 4E and 4F). We performed correlation analysis to determine whether there was any relationship between the in vitro cytokine production and the resultant gene expression in vivo in the recipient mouse myocardium. The hCMs demonstrated a significant correlation between the in vitro cytokine production versus in vivo gene expression of antiapoptotic cytokine (TNF-α and GCSF) versus gene (TNF-α; R=0.85 and P=0.04). Similarly, the iCM and iPSC groups showed a significant correlation in antiapoptotic cytokines (TNF-α and GCSF) versus genes (Akt1 and TNF-α; R=0.70 and P=0.012). This relationship suggests that the increased production of antiapoptotic cytokines by the hCMs and iCMs contributed to the reduction of apoptosis in the murine myocardium.
To validate the upregulation of antiapoptotic genes in the recipient myocardium, tissues were probed with TUNEL (terminal deoxynucleotidyl transferase dUTP nick end labeling) complex and costained with mouse TNNI3 (cardiac troponin 3) to detect DNA fragmentation. Fluorescence emitted by the TUNEL complex was normalized to Hoechst 33342 nuclear staining in TNNI3-positive cells. Consistent with our cytokine production and gene expression findings, TUNEL (apoptosis) signal in the PIR of hCM or iCM groups was significantly downregulated compared with control and trended downward compared with hESC or iPSC groups, respectively ( Figure 4C , 4D, 4G, and 4H). Apoptosis in remote-region cardiac myocytes was similar across all groups (Online Figure VI) .
Increased Cell Migration in the hCM/iCM-Treated Murine Myocardium
Our Luminex data indicated production of pleiotropic cytokines with antiapoptotic and promigratory effects. TNF-α, PAI1, VCAM1, and SDF1α were secreted at particularly high levels in hCMs and iCMs supernatant. TNF-α, which mediates both apoptosis and migration, was upregulated in the hCMtreated myocardium (P<0.3) and iCM-treated myocardium (*P<0.05; Figure 4B and 4F). The relationship between in vivo TNF-α gene expression and in vitro promigratory cytokine production was particularly significant (genes: TNF-α versus cytokines: TNF-α, PAI1, and VCAM1; R=0.80 and P=0.019). Additionally, connexin-43-a promigratory gene-was upregulated in the hCM and iCM groups ( Figure 5A and 5D) .
We verified these cytokine and gene expression findings by IHC analysis of promigration marker, CXCR4 (C-X-C chemokine receptor type 4). 34, 35 Consistent with PCR results, CXCR4 expression was significantly upregulated in hCM-or iCM-treated myocardium compared with pluripotent stem cell groups ( Figure 5B , 5C, 5E, and 5F). These findings indicate that the increased secretion of promigratory cytokines by hCMs and iCMs correlate with the upregulated migratory genes and markers in the PIR, which may have ultimately contributed to improved cardiac function post-MI.
Angiogenesis is Promoted in the hCM/iCM-Treated Murine Myocardium
Angiogenic cytokines (IL8, VEGF, PIGF1, and GCSF) were significantly increased in hCM and iCM groups (compared with hESC and iPSC groups, respectively). Ex vivo RT-PCR analysis revealed that the iCM-treated myocardium demonstrated upregulated angiogenic genes (Akt1, P<0.05 and VEGF, P<0.3 versus control group; Figure 6A and 6D). Secretion of angiogenic cytokines in iCMs in vitro and expression of VEGF in iCM group ex vivo were significantly correlated (cytokines: VEGF, PIGF1, and GCSF versus genes: Akt1 and VEGF; R=0.74 and P=0.00 049). To verify activation of the proangiogenic pathway in the recipient myocardium, we measured expression of CD31 by IHC. CD31-a marker for angiogenesis 36, 37 -was significantly overexpressed in the hCM-and iCM-treated myocardium ( Figure 6B , 6C, 6E, and 6F, P<0.05 versus hESC/iPSC groups), confirming the effect of proangiogenic cytokines from hCM and iCM supernatant.
Salvage Versus Regeneration of the Cell-Treated Myocardium
We investigated whether the restoration of the injured murine myocardium may be because of salvage of the injured cardiac myocytes or proliferation of new cells. To make this distinction, we studied expression of MLC2v (myosin regulatory light chain 2, ventricular isoform)-a marker for myocyte contractility in the PIR-and monitored host cell proliferation by injecting EdU (5-ethynyl-2′-deoxyuridine)-a nucleoside analog of thymidine that is actively incorporated into DNA during DNA synthesis. IHC analysis of the PIR showed little EdU signal in the PIR with no statistically significant difference between cardiac and pluripotent stem cell treatment groups (data not shown). There was, however, an upward trend of MLC2v expression in the hCM-or iCM-treated myocardium compared with control group (Figure 7A and 7D) . Similarly, IHC detected significant overexpression of MLC2v in the hCM and iCM groups compared with the hESC and iPSC groups, respectively ( Figure 7B , 7C, 7E, and 7F). These findings suggest that functional improvements in the hCM-or iCM-treated myocardium are not caused predominantly by recruitment of proliferating cells to regenerate de novo myocardium. Rather, cardiac stem cell therapy more likely restores the injured cardiac myocytes in the PIR.
We further explored the size of surviving cardiac myocytes in the PIR and remote region. The cross-sectional area of cardiac myocytes in the PIR of hCM and iCM groups was significantly greater than that of myocytes in the PIR of pluripotent stem cell-treated or control groups (Online Figure VIIA and  VIIC) . Myocytes in the remote regions were similar across all groups (Online Figure VIIB and VIID) . Myocyte nuclear density measurements revealed no significant difference between groups in the PIR or in the remote region (Online Figure VIIE through VIIH). These findings suggest that the recovery of the contractile elements may be linked to compensatory hypertrophy of the injured cardiac myocytes, which underlies the mechanism of action of salvage in the PIR. The improved survival, enhanced contractility, and hypertrophy of the injured cardiac myocytes by the paracrine effects of cells improve LVEF and myocardial viability post-MI.
Discussion
Acute MI results in cardiac myocyte death and progressive reduction in heart function, which eventually deteriorates to heart failure. 4 Although recent preclinical and clinical reports have shown that stem cell transplantation leads to improvement in LV function and viability, the underlying mechanism remains unclear. 25, 38 Although other investigations have described the paracrine mechanism, this study is, to the best of our knowledge, the first to systematically quantify pluripotent stem cell or pluripotent stem cell-derived cardiac myocyte cytokines and their in vivo target mechanism. Additionally, we compare 2 variants of pluripotent stem cells (hESCs and iPSCs) and their cardiac-lineage differentiated cells (hCMs and iCMs) with multiple assessments, including a direct in vivo evaluation of myocardial viability and function and in vitro measurement of myocyte cross-sectional area and immunohistology of myocardial apoptosis, fibrosis, angiogenesis, and cell migration. This rigorous and novel approach allowed real-time tracking of fundamental stem cell biology in vivo to enhance our understanding of the mechanism underlying myocardial restoration.
Results from this investigation indicate that pluripotent stem cell-derived cardiac myocytes are therapeutically more advantageous than their undifferentiated counterparts or the control in an ischemic MI model. Benefits of cardiac cell therapy, such as a significant improvement in LVEF and myocardial viability are attributed to enhanced engraftment as detected by BLI and confirmed by immunostaining of the hCM-and iCM-treated heart tissues at week 4. However, a significant volumetric discrepancy between the engrafted cells and the enhanced myocardial viability demonstrates clearly that the engrafted cells did not regenerate the myocardium but instead may have salvaged the existing injured cardiac myocytes in the PIR.
To understand the role of cytokines from transplanted cells, we performed in vitro analyses of the cell supernatants. Six paracrine factors (IL8, TNF-α, GCSF, VCAM1, VEGF, and PAI1) were found to be significantly more abundant in hCMs compared with hESCs. iCMs also produced 7 paracrine Figure 7 . Salvage vs regeneration of the stem cell therapy in the peri-infarct region (PIR). A, MLC2v gene expression was greater in the hESC-derived cardiac myocyte (hCM) group compared with the control and had an upward trend compared with the human embryonic stem cells (hESC) group. B, The PIR was identified using H&E staining and analyzed for MLC2v expression. C, Representative H&E and IHC images for MLC2v and EdU. D, MLC2v was overexpressed in the induced pluripotent stem cell (iPSC)-derived cardiac myocytes (iCM) group compared with the control group. E, There was significant MLC2v expression in the iCM group compared with the iPSC group. F, Representative H&E and IHC images for MLC2v and EdU. Data are presented as mean±SEM. *P<0.05, ‡P<0.3.
factors (SDF1α, PIGF1, TNF-α, GCSF, VCAM1, VEGF, and PAI1) at significantly higher levels than iPSCs. These paracrine factors lie upstream of important remodeling and healing pathways in the infarcted myocardium, which may have contributed to the antiapoptosis (TNF-α), 39 proangiogenesis (IL8, PIGF1, GCSF, and VEGF), [40] [41] [42] [43] [44] and procell migration (SDF1α, TNF-α, VCAM1, and PAI1) [45] [46] [47] [48] of injured cardiac myocytes in the PIR. To correlate the observed cytokine secretions with their subsequent genetic regulation in vivo, we probed the explanted hearts for evidence of transcriptional and translational effects of these cytokines, specifically in their known targets.
RT-PCR and IHC analyses at week 4 showed significant correlation with the observed Luminex data. Upregulation of Akt1 has been reported to play a critical role in cell survival and angiogenesis. 41, 49 Akt1 is activated by GCSF secretion and has been noted in iCMs through the PI3K/Akt pathway. 42 GCSF has also been reported to activate the intracellular signaling cascade of Jak/STAT pathway, which induces the expression of angiogenesis factors. 50 In this study, we found significant increases in both VEGF and GCSF cytokine production and associated VEGF and Akt1 gene expression in the myocardium of the iCM-treatment group. This finding is consistent with other studies, which report that PIGF1 Figure 8 . Schematic of the paracrine mechanism of hESC-derived cardiac myocyte (hCMs) and induced pluripotent stem cells (iPSC)-derived cardiac myocytes (iCMs) salvage of the injured myocardium. Summary of the correlation among immunohistology, significantly upregulated gene expression, and the associated cytokine productions in the myocardium treated with (A) hCMs and (B) iCMs. GCSF indicates granulocyte colony stimulating factor; LV, left ventricle; TGF, transforming growth factor; TNF, tumor necrosis factor; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling; and VEGF, vascular endothelial growth factor. September 1, 2017 cytokine secretion enhances the VEGF gene expression from the autocrine pathway and contributes to the angiogenesis in myocardial infarction. 44, 51 Our data are also in agreement with upregulation of PIGF1 cytokine secretion and VEGF gene expression in the iCM group. Ultimately, angiogenesis, as quantified by CD31 IHC, was upregulated in both hCM and iCM groups.
Moreover, TNF-α and connexin-43, which promote antiapoptosis 39 and cell migration, 45, 52 were significantly upregulated in the supernatant of cardiac stem cells and correlated with the significantly increased gene expression of TNF-α in hCM-and iCM-treated heart tissue. SDF1α was also significantly upregulated in the iCM supernatant compared with the iPSC. Apoptosis, as measured by TUNEL IHC, was significantly downregulated in cardiac stem cell-treated myocardium.
Although apoptosis in the postinfarct myocardium is extensively studied, the role of migration is less understood. Our data associate transplantation of cardiac stem cells in the PIR with enhanced cell migration. SDF1α, also known as CXC12, is a chemokine ligand of CXCR4 and is known to be upregulated after myocardial ischemia. 53 Injection of CXC12 was reported to reduce infarct size and increase cardiac function after MI. 54, 55 It, thus, follows that SDF1α secreted by hCMs and iCMs may activate CXCR4 to induce the same cardioprotective benefits. Although the role of CXCR4 in the ischemic heart is largely studied because it pertains to progenitor cell recruitment, other studies report that it activates Akt1 within resident endothelial cells and cardiac myocytes. [55] [56] [57] We explored whether enhanced cardiac function is attributed to regeneration or salvage of the myocardium. EdU injections and comparisons of nuclear density showed no substantial evidence of proliferating cells in any groups; however, hCMs and iCMs upregulated gene and protein expression of MLC2v in the PIR to enhance cardiac contractility. 58 These findings suggest that salvage of the injured cardiac myocytes, rather than recruitment of proliferative cells, underlie the significantly greater myocardial viability in the PIR and improved LVEF associated with cardiac stem cell therapy. Closer inspection of PIR cardiac myocytes revealed significantly larger cells in the hCM and iCM groups compared with the hESC and iPSC groups, respectively, or in comparison with the remote region of either group. These data indicate that the increase in cardiac myocyte size and recovery of the contractile element may accompany salvage of injured cardiac myocytes. Canonically, postinfarct hypertrophy is strongly associated with poor outcomes 59 ; some studies show, however, that hypertrophy in the absence of fibrogenesis may instead be beneficial and compensatory. 60 Our data show that the hypertrophied PIR of cardiac myocyte-treated myocardium had reduced apoptosis and fibrosis, suggesting that such hypertrophy may be physiological and repair heart function.
Herein, we present evidence that robust cardiac-lineage differentiated stem cell 13 is essential for effective stem cell therapy of ischemic MI. The clear discrepancy between their limited cellular engraftment and disproportionate increase in the myocardial viability in PIR provides compelling evidence of cardioprotective paracrine secretion 12, 17, 19 to modulate gene and protein expression in the injured cardiac myocytes to improved myocardial function (Figure 8 ). On the contrary, pluripotent stem cell-treated groups demonstrated decreased engraftment in vivo, and Luminex assays demonstrated diminished cytokine secretion in vitro. This finding supports the critical role of paracrine factors found in the stem cell-derived cardiac myocytes. Our histological analyses support the notion that the injured myocardium was salvaged rather than regenerated de novo from transplanted cardiac stem cells. We observed reduced apoptosis and infarct size with enhanced angiogenesis, cell migration, and myocyte contractility in cardiac stem cell-treated PIR. We also observed no difference in the population of proliferating endogenous cells between all groups. Thus, the regenerative mechanism, which requires cell engraftment and direct electromechanical contribution to the myocardial function, did not represent the dominant underlying mechanism in the improved heart function. This supports other work that reports stem cell-mediated myocardium regeneration to be a rare occurrence.
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Limitations
This study has some limitations. First, we measured cytokine secretions from the supernatant of cultured cells. This experimental method does not provide any direct insight into the in vivo cellular secretomes and immunologic response of engrafted cells after their delivery into infarcted regions. Engrafted cells in the infarcted myocardium, exposed to the hypoxic and inflammatory in vivo niche, may respond differently from the cultured conditions. Second, all surgical operations were conducted by an experienced and blinded microsurgeon. The murine MI model is consistent, but the efficacy and reliability of cell injections into the infarcted mouse myocardium may vary because the delivery efficacy is difficult to confirm. Third, the PIR of the myocardium may have included the remote area for RT-PCR because of the minute size of the murine heart. Fourth, cardiac lineage cells (hCMs and iCMs) in this acute chronic ischemia model may have a different effect in patients with advanced heart failure.
In summary, this study provides a mechanistic correlation between the fundamental biological parameters of cardiac lineage stem cells and their physiological effects on myocardium salvage. Cardiac differentiation of pluripotent stem cells resulted in improved engraftment and subsequent restoration of LV function and myocardial viability compared with the undifferentiated pluripotent stem cells (hESCs and iPSCs) and control. This difference delineated the important effects of the underlying paracrine mechanism of action of the cardiac lineage derivatives of pluripotent stem cells. This investigation found considerable discrepancy between the microscopic volume of the engrafted cells and the volume of myocardial viability. The data indicated that hCMs and iCMs salvaged the injured myocardium effectively by their differential paracrine effects.
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